206 related articles for article (PubMed ID: 15388423)
1. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.
Delaney WE; Yang H; Miller MD; Gibbs CS; Xiong S
Antimicrob Agents Chemother; 2004 Oct; 48(10):3702-10. PubMed ID: 15388423
[TBL] [Abstract][Full Text] [Related]
2. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.
Seifer M; Patty A; Serra I; Li B; Standring DN
Antiviral Res; 2009 Feb; 81(2):147-55. PubMed ID: 19028525
[TBL] [Abstract][Full Text] [Related]
3. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Zhu Y; Curtis M; Qi X; Miller MD; Borroto-Esoda K
Antivir Chem Chemother; 2009; 19(4):165-76. PubMed ID: 19374144
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
Qi X; Xiong S; Yang H; Miller M; Delaney WE
Antivir Ther; 2007; 12(3):355-62. PubMed ID: 17591025
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
7. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Niu C; Bao H; Tolstykh T; Micolochick Steuer HM; Murakami E; Korba B; Furman PA
Antivir Ther; 2010; 15(3):401-12. PubMed ID: 20516559
[TBL] [Abstract][Full Text] [Related]
9. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Leemans WF; Janssen HL; Niesters HG; de Man RA
J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
Ijaz S; Arnold C; Dervisevic S; Mechurova J; Tatman N; Tedder RS; Naoumov NV
J Med Virol; 2008 Jul; 80(7):1160-70. PubMed ID: 18461609
[TBL] [Abstract][Full Text] [Related]
11. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance.
Zoulim F
Semin Liver Dis; 2002; 22 Suppl 1():23-31. PubMed ID: 12447726
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
[TBL] [Abstract][Full Text] [Related]
13. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
Billioud G; Pichoud C; Puerstinger G; Neyts J; Zoulim F
Antiviral Res; 2011 Nov; 92(2):271-6. PubMed ID: 21871497
[TBL] [Abstract][Full Text] [Related]
14. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil.
Delaney WE
J Antimicrob Chemother; 2007 May; 59(5):827-32. PubMed ID: 17332007
[TBL] [Abstract][Full Text] [Related]
15. Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities.
Ying C; Holy A; Hocková D; Havlas Z; De Clercq E; Neyts J
Antimicrob Agents Chemother; 2005 Mar; 49(3):1177-80. PubMed ID: 15728921
[TBL] [Abstract][Full Text] [Related]
16. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
Cho SW; Koh KH; Cheong JY; Lee MH; Hong SP; Yoo WD; Kim SO
J Viral Hepat; 2010 Mar; 17(3):171-7. PubMed ID: 19678894
[TBL] [Abstract][Full Text] [Related]
17. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
[TBL] [Abstract][Full Text] [Related]
18. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
[TBL] [Abstract][Full Text] [Related]
19. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
[TBL] [Abstract][Full Text] [Related]
20. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis.
Ohkawa K; Takehara T; Kato M; Kanada A; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Med Virol; 2009 May; 81(5):798-806. PubMed ID: 19319954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
